Should You Subscribe to the IPO of Medline Inc

The Offer

Company Overview

Medline Inc. (MDLN) is the largest provider of medical-surgical products and integrated supply-chain solutions in the U.S., offering approximately 335,000 mission-critical items across all care settings and distributing them through a vast global logistics network of 69 facilities and over 2,000 owned trucks, enabling next-day delivery to 95% of U.S. customers. Built on a vertically integrated model combining manufacturing, sourcing, and distribution, Medline leverages its Medline Brand and Supply Chain Solutions segments to deliver high-quality, cost-efficient products and services, strengthening long-term Prime Vendor partnerships that create visibility into customer demand and reinforce a recurring revenue base that has compounded at 18% annually since inception. The company’s expansive product portfolio, differentiated logistics capabilities, and customer-centric culture—supported by a 3,800-member commercial team—enable Medline to expand wallet share, enhance operating efficiency, and drive superior value across hospitals, ambulatory centers, physician offices, and post-acute facilities. With a track record of consistent organic growth, resilience through economic cycles, and a portfolio dominated by recurring consumables, Medline is well positioned to capitalize on rising healthcare utilization, customer consolidation, channel expansion, new product development, selective M&A, and international scaling to sustain long-term revenue and earnings growth.

Key Highlights

Primary Offering:

179,000,000 shares (or 205,850,000 shares if the underwriters exercise in full their option to purchase additional shares of Class A common stock)

Use of proceeds:

Primary Use of Base Offering Proceeds: Medline Inc. expects to generate approximately USD 4.899 billion in net proceeds from the base offering at an assumed IPO price of USD 28 per share, with sensitivity of roughly USD 175 million for every USD 1 change in the IPO price. These funds will be used to acquire an equivalent number of newly issued Common Units from Medline Holdings, aligning with the planned organizational and capital structure transactions described in the prospectus.

Debt Repayment and Corporate Allocation Strategy: Medline Holdings will deploy approximately USD 729 million of these proceeds to fully repay the outstanding balance under the New Euro Term Loan Facility and USD 3.280 billion to partially repay the 2028 Refinancing Term Loan Facility, with both loans maturing in October 2028 and carrying variable interest structures linked to EURIBOR or SOFR benchmarks. The remaining proceeds will support general corporate purposes and cover estimated offering expenses of USD 38 million, thereby strengthening Medline’s balance sheet and reducing interest burdens through refinancing of previously higher-margin term loans.

Use of Additional Proceeds from Over-Allotment Option: If underwriters exercise their option to purchase up to 26.85 million additional shares, Medline anticipates receiving roughly USD 735 million in incremental proceeds, which will be used exclusively to purchase or redeem outstanding Common Units and Class A shares from certain pre-IPO owners at the IPO price net of underwriting discounts. These proceeds will not be retained by Medline, but will instead facilitate ownership transitions outlined in the organizational structure and principal stockholder disclosures.

Dividend policy:

Medline Inc. does not currently plan to pay dividends on its Class A common stock, and any future dividend decisions will rest solely with the board based on cash availability, legal constraints, debt covenants, and broader financial considerations. As a holding company, Medline Inc. depends entirely on distributions from Medline Holdings to fund taxes, expenses, tax receivable agreement obligations, and any dividends it may declare, with all Common Unit holders receiving distributions on a pro rata basis. While excess cash from tax distributions may allow Medline Inc. to fund share repurchases, acquire additional Common Units, or potentially pay dividends, multiple credit-agreement covenants and Delaware law impose significant restrictions on upstreaming distributions. Accordingly, dividend payments, if any, are likely to be limited and conditional on both operational performance and compliance with financing and legal constraints.

Market Opportunity Overview

• Global and U.S. Market Scope: Medline identifies a total addressable market of approximately USD 375 billion globally, with the U.S. contributing roughly USD 175 billion across acute and non-acute care settings, and international markets representing about USD 200 billion. The U.S. med-surg market benefits from structurally non-cyclical healthcare demand, supported by sixty consecutive years of spending growth, and is expected to expand further due to demographic aging and rising chronic disease prevalence, driving national health expenditures at an estimated 5.6% annual growth rate through 2032.
• International Growth Potential: Despite Medline’s scale, international sales remain a modest 6.9% of total revenue as of 2024, presenting a meaningful long-term expansion opportunity. Global acute and non-acute care markets exhibit similar secular tailwinds and growing demand for resilient supply chain partners, positioning Medline to increase penetration as healthcare utilization rises and health systems pursue consolidation and efficiency.
• Structural Tailwinds Supporting Opportunity: Several industry dynamics reinforce Medline’s market opportunity, including margin pressure on healthcare providers that increases demand for cost-efficient supply chain solutions, the shift of higher-acuity care to lower-cost settings such as surgery centers and clinics, continued consolidation across health systems, and an elevated emphasis on supply chain resiliency following years of disruption-driven shortages.
• Medline Brand Market Positioning: Within this broader opportunity, Medline’s Brand segment addresses a serviceable market of approximately USD 75 billion with leadership positions across its product families in Front Line Care, Surgical Solutions, and Laboratory and Diagnostics. Supported by significant in-house manufacturing capabilities and a diversified global sourcing network, Medline’s value proposition—combining product breadth, quality, and efficiency—reinforces its ability to capture incremental share across both acute and non-acute channels.

Financial Highlights (Results of Operations) (Expressed in USD)

• Sustained Market Leadership and Revenue Durability: Medline’s scale, vertically integrated distribution model, and broad med-surg portfolio underpin a resilient revenue base that has expanded at an 18% CAGR since inception. For the nine months ended September 27, 2025, the company generated USD 20.6 billion in net sales and USD 2.7 billion in Adjusted EBITDA, with Medline Brand remaining the primary profitability driver despite modest margin compression from tariff-related cost pressures.
• Segment Contributions and Margin Trends: Medline Brand delivered USD 10.0 billion in segment sales and USD 2.5 billion in Segment Adjusted EBITDA, supported by strong growth across Surgical Solutions, Front Line Care, and Laboratory & Diagnostics, although higher import and product costs weighed on margins. Supply Chain Solutions grew 11.6% to USD 10.6 billion and showed improving operating leverage, but continued to operate at structurally lower margins due to its third-party distribution economics.
• Revenue Drivers, Cost Behaviour, and Operational Efficiency: Growth in 2025 was almost entirely volume-driven across both U.S. and international markets, supported by expanding Prime Vendor relationships and strong demand across care settings. Gross margin declined slightly to 27.1% as tariff-driven cost increases offset sourcing efficiencies, and SG&A rose in line with revenue due to expanded headcount, acquisitions, and distribution activity, though lower refinancing expenses partially mitigated cost pressures.
• Liquidity Strength and Balance Sheet Deleveraging: With USD 952 million in cash and robust revolver availability, Medline maintains solid liquidity, further strengthened by the planned USD 4.899 billion equity raise earmarked for targeted debt repayment. Continued investment in manufacturing expansion, automation, and logistics supports long-term scale efficiencies, and management expresses confidence in the company’s ability to meet operational and capital requirements despite macroeconomic and FX-related uncertainties.

Key Management Highlights

Risk Associated (High)

Investment in the IPO of “MDLN” is exposed to a variety of risks such as:

• Margin Compression Risk from Tariffs, Import Costs, and Product Mix Shifts: Medline faces ongoing pressure from higher import tariffs, elevated sourcing costs, and the structural margin differential between Medline Brand and third-party Supply Chain Solutions products; sustained cost inflation or slower-than-expected conversion to Medline Brand could further erode gross margins.
• Dependence on Prime Vendor Model and Large Health System Relationships: A significant share of revenue growth relies on expanding and retaining long-term Prime Vendor contracts; any disruption, non-renewal, or competitive displacement within these large, consolidated customer relationships could materially impact sales volumes and profitability.
• Execution and Capital Intensity Risks Linked to Manufacturing, Distribution, and Expansion Investments: Medline’s strategy requires continuous large-scale capital investment in manufacturing automation, logistics, and distribution capacity; delays, cost overruns, or operational issues—especially within its global sourcing network—could impair service levels, increase operating costs, and weaken competitive positioning.

Conclusion

JM Group Limited (JMG) is a Hong Kong–based sourcing solutions provider that supplies a broad range of consumer products across eight major categories to customers in markets including the U.S., Australia, Mexico, and Hong Kong, supported by in-house design, product development, and quality management capabilities. Through its IPO, the Company plans to raise approximately USD 14.86 million, which intends to allocate evenly toward brand promotion, talent recruitment, strategic investments, and general working capital, with flexibility retained for future adjustments. JMG operates within several expanding global markets—including home and tools, seasonal décor, sports and outdoors, and toys and games—each driven by long-term trends such as rising disposable income, increased health and lifestyle awareness, demand for customization, and growth of e-commerce, though each faces constraints ranging from economic sensitivity to supply-chain and regulatory pressures. Financially, JMG reported a 14.1% increase in revenue for the six months ended March 31, 2025, stronger profitability driven by lower SG&A due to a major credit-loss reversal, and improved operating cash flow alongside modest increases in merchandise costs tied to higher sales volume. Key risks include co
ncentration of revenue with a major U.S. customer, reliance on mainland China suppliers, and exposure to margin pressures within highly competitive, price-sensitive product categories.

Hence, given the financial performance of the company, use of proceeds, and associated risks “Medline Inc. (MDLN)” IPO seems “Neutral" at the IPO price.